8-K Announcements
6Material company update
Mar 10, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Feb 26, 2026·SEC
vTv Therapeutics Inc.(VTVT)Earnings, Financials & Key Ratios
VTVT•NASDAQ
$31.68
$267M mkt cap·Price updated May 6, 2026
AboutvTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.Show more
- Revenue$0-100.0%
- EBITDA-$33M-36.1%
- Net Income-$27M-46.1%
- EPS (Diluted)-3.20
- ROE-68.52%+46.9%
- Interest Coverage-5468.00
VTVT Key Insights
vTv Therapeutics Inc. (VTVT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 46.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VTVT Price & Volume
vTv Therapeutics Inc. (VTVT) stock price & volume — 10-year historical chart
Loading chart...
VTVT Growth Metrics
vTv Therapeutics Inc. (VTVT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-102.36%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-46.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM4.01%
Return on Capital
10 Years-193.07%
5 Years-134.88%
3 Years-132.53%
Last Year-56.41%
VTVT Recent Earnings
vTv Therapeutics Inc. (VTVT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 10, 2026EPS
$0.58
Est $0.98
+40.8%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$1.08
Est $0.97
-11.3%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.92
Est $0.85
-8.2%
Revenue
—
Q2 2025
May 15, 2025EPS
$0.77
Est $0.73
-5.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 10, 2026 | $0.58vs $0.98+40.8% | — |
| Q4 2025 | Nov 6, 2025 | $1.08vs $0.97-11.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.92vs $0.85-8.2% | — |
| Q2 2025 | May 15, 2025 | $0.77vs $0.73-5.5% | — |
Based on last 12 quarters of dataView full earnings history →
VTVT Peer Comparison
vTv Therapeutics Inc. (VTVT) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 | |||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 LGND | 4.57B | 232.55 | -1057.05 | 27.28% | 19.34% | 5.11% | 0.01 |
Compare VTVT vs Peers
vTv Therapeutics Inc. (VTVT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VTVT Income Statement
vTv Therapeutics Inc. (VTVT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 291K | 12.43M | 2.76M | 6.41M | 4M | 2.02M | 0 | 1.02M | 0 |
| Revenue Growth % | -54.1% | 4172.85% | -77.77% | 132.05% | -37.56% | -49.61% | -100% | - | -100% |
| Cost of Goods Sold | 39.64M | 23.04M | 15.12M | 11.02M | 0 | 0 | 0 | 0 | 16K |
| COGS % of Revenue | 13621.99% | 185.26% | 547% | 171.73% | - | - | - | - | - |
| Gross Profit | -39.35M▲ 0% | -10.6M▲ 73.1% | -12.36M▼ 16.5% | -4.6M▲ 62.8% | 4M▲ 187.0% | 2.02M▼ 49.6% | 0▼ 100.0% | 1.02M▲ 0% | -16K▼ 101.6% |
| Gross Margin % | -13521.99% | -85.26% | -447% | -71.73% | 100% | 100% | - | 100% | - |
| Gross Profit Growth % | 12.78% | 73.06% | -16.55% | 62.76% | 187.05% | -49.61% | -100% | - | -101.57% |
| Operating Expenses | 50.97M | 32.26M | 23.66M | 7.25M | 25.67M | 24.56M | 25.5M | 25.2M | 32.81M |
| OpEx % of Revenue | 17516.49% | 259.43% | 855.86% | 113.05% | 640.87% | 1216.95% | - | 2477.58% | - |
| Selling, General & Admin | 11.33M | 9.22M | 8.54M | 7.25M | 12.34M | 12.2M | 11.91M | 13.65M | 14.95M |
| SG&A % of Revenue | 3894.5% | 74.18% | 308.86% | 113.05% | 308.19% | 604.61% | - | 1342.28% | - |
| Research & Development | 39.64M | 23.04M | 15.12M | 11.02M | 13.32M | 12.36M | 13.6M | 11.55M | 17.86M |
| R&D % of Revenue | 13621.99% | 185.26% | 547% | 171.73% | 332.68% | 612.34% | - | 1135.3% | - |
| Other Operating Expenses | -190K | -592K | 0 | -11.02M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -50.68M▲ 0% | -19.82M▲ 60.9% | -20.89M▼ 5.4% | -11.85M▲ 43.3% | -21.66M▼ 82.8% | -22.54M▼ 4.1% | -25.5M▼ 13.1% | -24.18M▲ 5.2% | -32.81M▼ 35.7% |
| Operating Margin % | -17416.49% | -159.43% | -755.86% | -184.78% | -540.87% | -1116.95% | - | -2377.58% | - |
| Operating Income Growth % | 7.88% | 60.89% | -5.39% | 43.27% | -82.77% | -4.05% | -13.14% | 5.18% | -35.68% |
| EBITDA | -50.48M | -19.61M | -20.85M | -11.76M | -21.57M | -22.45M | -25.41M | -24.09M | -32.79M |
| EBITDA Margin % | -17348.8% | -157.68% | -754.45% | -183.32% | -538.65% | -1112.39% | - | -2368.83% | - |
| EBITDA Growth % | 7.8% | 61.16% | -6.36% | 43.61% | -83.48% | -4.06% | -13.2% | 5.2% | -36.12% |
| D&A (Non-Cash Add-back) | 197K | 218K | 39K | 94K | 89K | 92K | 90K | 89K | 16K |
| EBIT | -50.76M | -20.36M | -20.01M | -12.11M | -17.6M | -24.86M | -25.95M | -22.61M | -32.81M |
| Net Interest Income | -2.98M | -3.23M | -1.77M | -680K | -11K | 337K | 459K | 1.56M | 1.86M |
| Interest Income | 117K | 61K | 53K | 12K | 1K | 352K | 472K | 1.56M | 1.87M |
| Interest Expense | 3.09M | 3.29M | 1.83M | 692K | 12K | 15K | 13K | 0 | 6K |
| Other Income/Expense | -3.17M | -3.82M | -946K | -950K | 4.05M | -2.33M | -464K | 1.57M | 1.73M |
| Pretax Income | -53.85M▲ 0% | -23.64M▲ 56.1% | -21.84M▲ 7.6% | -12.8M▲ 41.4% | -17.62M▼ 37.6% | -24.87M▼ 41.2% | -25.97M▼ 4.4% | -22.61M▲ 12.9% | -31.08M▼ 37.5% |
| Pretax Margin % | -18504.12% | -190.16% | -790.09% | -199.59% | -439.85% | -1232.56% | - | -2222.71% | - |
| Income Tax | 800K | 200K | 100K | 0 | 115K | 200K | 0 | 100K | 0 |
| Effective Tax Rate % | -1.49% | -0.85% | -0.46% | 0% | -0.65% | -0.8% | 0% | -0.44% | 0% |
| Net Income | -16.14M▲ 0% | -7.91M▲ 51.0% | -21.94M▼ 177.3% | -8.5M▲ 61.3% | -12.99M▼ 52.8% | -19.16M▼ 47.6% | -20.25M▼ 5.7% | -18.46M▲ 8.8% | -26.97M▼ 46.1% |
| Net Margin % | -5547.77% | -63.62% | -793.7% | -132.51% | -324.27% | -949.65% | - | -1815.34% | - |
| Net Income Growth % | 1.27% | 51% | -177.31% | 61.26% | -52.81% | -47.56% | -5.67% | 8.83% | -46.11% |
| Net Income (Continuing) | -54.65M | -23.84M | -21.94M | -12.8M | -17.73M | -25.07M | -25.97M | -22.7M | -31.08M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 131.44M | 62.48M | 40.18M | 83.89M | 24.96M | 16.58M | 6.13M | 2.1M | 0 |
| EPS (Diluted) | -66.62▲ 0% | -25.42▲ 61.8% | -28.97▼ 14.0% | -7.21▲ 75.1% | -8.29▼ 15.0% | -9.98▼ 20.4% | -9.71▲ 2.7% | -3.20▲ 67.0% | -3.20▲ 0.0% |
| EPS Growth % | 2.77% | 61.84% | -13.97% | 75.11% | -14.98% | -20.39% | 2.71% | 67.04% | 0% |
| EPS (Basic) | -66.62 | -25.42 | -28.97 | -7.21 | -8.29 | -9.98 | -9.71 | -3.20 | -3.20 |
| Diluted Shares Outstanding | 242.33K | 311.23K | 757.3K | 1.18M | 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
| Basic Shares Outstanding | 242.33K | 311.23K | 757.3K | 1.18M | 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
VTVT Balance Sheet
vTv Therapeutics Inc. (VTVT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 20.36M | 3.47M | 2.84M | 7.21M | 15.62M | 27.09M | 10.66M | 38.11M | 89.89M |
| Cash & Short-Term Investments | 11.76M | 1.68M | 1.78M | 5.75M | 13.41M | 12.13M | 9.45M | 36.75M | 88.93M |
| Cash Only | 11.76M | 1.68M | 1.78M | 5.75M | 13.41M | 12.13M | 9.45M | 36.75M | 88.93M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8M | 0 | 5K | 158K | 57K | 12.42M | 102K | 62K | 0 |
| Days Sales Outstanding | 10.03K | - | 0.66 | 8.99 | 5.19 | 2.25K | - | 22.25 | - |
| Inventory | 162K | 0 | 0 | 371K | 100K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 1.49 | - | - | 12.29 | - | - | - | - | - |
| Other Current Assets | 442K | 666K | 0 | 0 | 35K | 0 | 0 | 0 | 961K |
| Total Non-Current Assets | 7.55M | 5.09M | 6.43M | 7.57M | 9.85M | 6.14M | 361K | 153K | 6K |
| Property, Plant & Equipment | 283K | 70K | 1M | 849K | 680K | 556K | 361K | 153K | 0 |
| Fixed Asset Turnover | 1.03x | 177.63x | 2.75x | 7.55x | 5.89x | 3.63x | - | 6.65x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 2.48M | 2.48M | 2.48M | 6.72M | 9.17M | 5.59M | 0 | 0 | 0 |
| Other Non-Current Assets | 4.79M | 2.54M | 2.94M | 0 | 0 | 0 | 0 | 0 | 6K |
| Total Assets | 27.92M▲ 0% | 8.56M▼ 69.3% | 9.27M▲ 8.3% | 14.79M▲ 59.6% | 25.47M▲ 72.2% | 33.24M▲ 30.5% | 11.02M▼ 66.9% | 38.27M▲ 247.3% | 89.9M▲ 134.9% |
| Asset Turnover | 0.01x | 1.45x | 0.30x | 0.43x | 0.16x | 0.06x | - | 0.03x | - |
| Asset Growth % | -48.77% | -69.34% | 8.26% | 59.6% | 72.25% | 30.48% | -66.85% | 247.3% | 134.93% |
| Total Current Liabilities | 26.93M | 18.84M | 13.38M | 6.39M | 8.5M | 7.71M | 10.62M | 5.2M | 6.64M |
| Accounts Payable | 2.27M | 2.9M | 2.23M | 1.93M | 1.88M | 2.46M | 4.08M | 939K | 1.13M |
| Days Payables Outstanding | 20.89 | 45.94 | 53.88 | 63.79 | - | - | - | - | 25.82K |
| Short-Term Debt | 4.27M | 9.38M | 6.17M | 84K | 256K | 224K | 191K | 0 | 0 |
| Deferred Revenue (Current) | 8.76M | 1.75M | 31K | 31K | 35K | 17K | 17K | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 1.56M | 1.59M | 3.2M | 788K | 4.7M | 1.51M | 5.51M |
| Current Ratio | 0.76x | 0.18x | 0.21x | 1.13x | 1.84x | 3.52x | 1.00x | 7.34x | 13.54x |
| Quick Ratio | 0.75x | 0.18x | 0.21x | 1.07x | 1.83x | 3.52x | 1.00x | 7.34x | 13.54x |
| Cash Conversion Cycle | 10.01K | - | - | -42.5 | - | - | - | - | - |
| Total Non-Current Liabilities | 152.03M | 72.58M | 4.72M | 4.61M | 1.75M | 19.69M | 18.95M | 18.77M | 18.82M |
| Long-Term Debt | 15.32M | 6.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 831K | 676K | 492K | 338K | 169K | 0 | 0 |
| Deferred Tax Liabilities | 131.93M | 64.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 782K | 2.7M | 2.86M | 2.92M | 1.26M | 684K | 110K | 100K | 18.82M |
| Total Liabilities | 178.96M | 91.41M | 18.11M | 11M | 10.25M | 27.4M | 29.57M | 23.96M | 25.46M |
| Total Debt | 19.59M | 15.71M | 7.11M | 915K | 932K | 716K | 529K | 169K | 0 |
| Net Debt | 7.83M | 14.03M | 5.34M | -4.83M | -12.48M | -11.41M | -8.92M | -36.58M | -88.93M |
| Debt / Equity | - | - | - | 0.24x | 0.06x | 0.12x | - | 0.01x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -16.39x | -6.03x | -11.44x | -17.13x | -1805.17x | -1502.67x | -1961.69x | - | -5468.00x |
| Total Equity | -19.61M▲ 0% | -20.37M▼ 3.9% | -8.84M▲ 56.6% | 3.79M▲ 142.9% | 15.22M▲ 301.3% | 5.84M▼ 61.6% | -18.55M▼ 417.7% | 14.3M▲ 177.1% | 64.44M▲ 350.6% |
| Equity Growth % | -162.11% | -3.9% | 56.61% | 142.91% | 301.32% | -61.64% | -417.67% | 177.1% | 350.58% |
| Book Value per Share | -80.91 | -65.45 | -11.67 | 3.22 | 9.72 | 3.04 | -8.90 | 2.48 | 7.65 |
| Total Shareholders' Equity | -151.05M | -82.85M | -49.02M | -80.1M | -9.74M | -10.74M | -24.68M | 12.2M | 64.44M |
| Common Stock | 329K | 435K | 641K | 773K | 901K | 27K | 27K | 32K | 39K |
| Retained Earnings | -279.06M | -233.88M | -233.52M | -290.04M | -248.83M | -265.52M | -281.04M | -299.72M | -326.69M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -9.12M | -8.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 131.44M | 62.48M | 40.18M | 83.89M | 24.96M | 16.58M | 6.13M | 2.1M | 0 |
VTVT Cash Flow Statement
vTv Therapeutics Inc. (VTVT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -44.56M | -26.86M | -23.02M | -18M | -19.31M | -15.25M | -19.08M | -25.31M | -25.25M |
| Operating CF Margin % | -15312.71% | -215.99% | -832.78% | -280.64% | -482.1% | -755.5% | - | -2488.4% | - |
| Operating CF Growth % | 7.57% | 39.73% | 14.29% | 21.8% | -7.27% | 21.04% | -25.15% | -32.63% | 0.21% |
| Net Income | -54.65M | -23.84M | -21.94M | -12.8M | -17.73M | -19.16M | -20.25M | -22.7M | -31.08M |
| Depreciation & Amortization | 197K | 218K | 39K | 94K | 89K | 92K | 90K | 89K | 16K |
| Stock-Based Compensation | 3.65M | 2.68M | 1.52M | 1.01M | 2.36M | 0 | 1.58M | 2.76M | 3.77M |
| Deferred Taxes | 179K | 626K | -1.11M | -3.98M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.03M | 1.01M | 532K | 380K | -4.06M | -1.56M | -4.89M | -10K | 142K |
| Working Capital Changes | 5.04M | -7.54M | -2.05M | -2.71M | 35K | 5.38M | 4.39M | -5.44M | 1.89M |
| Change in Receivables | -8M | 8M | -5K | -153K | 101K | -116K | 71K | 40K | 0 |
| Change in Inventory | 194K | 0 | 618K | -1.98M | -889K | 0 | 0 | 0 | 0 |
| Change in Payables | 2.45M | -6.2M | -618K | -997K | 1.83M | -856K | 2.93M | 0 | 1.53M |
| Cash from Investing | -25K | 7K | 242K | 0 | 0 | -21K | 4.4M | 0 | 0 |
| Capital Expenditures | -57K | -5K | -70K | 0 | 0 | -21K | 0 | 0 | 0 |
| CapEx % of Revenue | 19.59% | 0.04% | 2.53% | - | - | 1.04% | - | - | - |
| Acquisitions | 32K | 12K | 312K | 0 | 0 | 0 | 4.4M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 32K | 12K | 0 | 0 | 0 | 0 | -4.4M | 0 | 0 |
| Cash from Financing | 7.5M | 16.61M | 22.87M | 19.47M | 26.98M | 13.98M | 12M | 52.61M | 77.44M |
| Debt Issued (Net) | 7.5M | -4.89M | -10.07M | -4.96M | 172K | -808K | -33K | -191K | -392K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 302K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 47K | 0 | 0 | 0 | 341K |
| Net Change in Cash | -37.09M▲ 0% | -10.24M▲ 72.4% | 94K▲ 100.9% | 1.47M▲ 1463.8% | 7.67M▲ 421.6% | -1.29M▼ 116.8% | -2.68M▼ 107.9% | 27.3M▲ 1118.7% | 52.19M▲ 91.2% |
| Free Cash Flow | -44.62M▲ 0% | -26.86M▲ 39.8% | -23.09M▲ 14.0% | -18M▲ 22.0% | -19.31M▼ 7.3% | -15.27M▲ 20.9% | -19.08M▼ 25.0% | -25.31M▼ 32.6% | -25.25M▲ 0.2% |
| FCF Margin % | -15332.3% | -216.03% | -835.31% | -280.64% | -482.1% | -756.54% | - | -2488.4% | - |
| FCF Growth % | 7.62% | 39.8% | 14.05% | 22.04% | -7.27% | 20.93% | -24.98% | -32.63% | 0.21% |
| FCF per Share | -184.12 | -86.31 | -30.49 | -15.27 | -12.33 | -7.95 | -9.15 | -4.39 | -3.00 |
| FCF Conversion (FCF/Net Income) | 2.76x | 3.39x | 1.05x | 2.12x | 1.49x | 0.80x | 0.94x | 1.37x | 0.94x |
| Interest Paid | 0 | 2.28M | 1.29M | 0 | 11K | 0 | 0 | 2K | 0 |
| Taxes Paid | 0 | 1M | 100K | 0 | 115K | 0 | 0 | 100K | 0 |
VTVT Key Ratios
vTv Therapeutics Inc. (VTVT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -28.41% | -269.9% | - | - | -224.07% | -136.6% | -181.99% | - | -129.1% | -68.52% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -1911.35% | - | - | - | - |
| Gross Margin | -7115.77% | -13521.99% | -85.26% | -447% | -71.73% | 100% | 100% | - | 100% | - |
| Net Margin | -2579.18% | -5547.77% | -63.62% | -793.7% | -132.51% | -324.27% | -949.65% | - | -1815.34% | - |
| Debt / Equity | 0.35x | - | - | - | 0.24x | 0.06x | 0.12x | - | 0.01x | - |
| Interest Coverage | -138.24x | -16.39x | -6.03x | -11.44x | -17.13x | -1805.17x | -1502.67x | -1961.69x | - | -5468.00x |
| FCF Conversion | 2.95x | 2.76x | 3.39x | 1.05x | 2.12x | 1.49x | 0.80x | 0.94x | 1.37x | 0.94x |
| Revenue Growth | 22.16% | -54.1% | 4172.85% | -77.77% | 132.05% | -37.56% | -49.61% | -100% | - | -100% |
VTVT SEC Filings & Documents
vTv Therapeutics Inc. (VTVT) SEC filings — annual & quarterly reports (10-K, 10-Q)
VTVT Frequently Asked Questions
vTv Therapeutics Inc. (VTVT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
vTv Therapeutics Inc. (VTVT) reported $-0.0M in revenue for fiscal year 2025. This represents a 102% decrease from $1.0M in 2013.
vTv Therapeutics Inc. (VTVT) saw revenue decline by 100.0% over the past year.
vTv Therapeutics Inc. (VTVT) reported a net loss of $27.0M for fiscal year 2025.
Dividend & Returns
vTv Therapeutics Inc. (VTVT) has a return on equity (ROE) of -68.5%. Negative ROE indicates the company is unprofitable.
vTv Therapeutics Inc. (VTVT) had negative free cash flow of $25.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More VTVT
vTv Therapeutics Inc. (VTVT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates